Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
Type:
Application
Filed:
April 22, 2010
Publication date:
May 5, 2011
Inventors:
Ugur Sahin, Özlem Türeci, Michael Koslowski
Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
Type:
Application
Filed:
April 13, 2011
Publication date:
August 4, 2011
Inventors:
Ugur Sahin, Özlzem Türeci, Michael Koslowski, Dirk Usener
Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
Type:
Application
Filed:
January 20, 2014
Publication date:
May 15, 2014
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski
Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
Type:
Application
Filed:
August 25, 2008
Publication date:
March 26, 2009
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski
Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
Type:
Application
Filed:
September 6, 2006
Publication date:
August 13, 2009
Inventors:
Ugur Sahin, Özlem Türeci, Michael Koslowski, Dirk Usener
Abstract: The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
Type:
Application
Filed:
October 1, 2013
Publication date:
July 3, 2014
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski
Abstract: According to the invention, tumour-associated gene products and nucleic acids coding therefor were identified. The present invention relates to the therapy and diagnosis of diseases wherein said tumour-associated gene products are expressed aberrantly. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumour-associated manner and the nucleic acids coding therefor.
Type:
Application
Filed:
September 23, 2004
Publication date:
July 10, 2008
Applicant:
GANYMED PHARMACEUTICALS AG
Inventors:
Ozlem Tureci, Ugur Sahin, Gerd Helftenbein, Volker Schluter
Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
Type:
Application
Filed:
August 25, 2008
Publication date:
March 26, 2009
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski
Abstract: The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
Type:
Application
Filed:
April 14, 2009
Publication date:
August 20, 2009
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski
Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
Type:
Application
Filed:
July 18, 2011
Publication date:
January 19, 2012
Inventors:
Ugur Sahin, Özlem Türeci, Michael Koslowski
Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
Type:
Application
Filed:
April 22, 2010
Publication date:
March 22, 2012
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski
Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
Type:
Application
Filed:
November 15, 2011
Publication date:
October 11, 2012
Applicant:
GANYMED PHARMACEUTICALS AG
Inventors:
Ugur Sahin, Özlem Türeci, Michael Koslowski
Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
Type:
Application
Filed:
November 24, 2006
Publication date:
July 2, 2009
Inventors:
Ugur Sahin, Ozlem Tureci, Dirk Usener, Stefan Fritz, Cristoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schroder, Philippe Thiel
Abstract: The invention relates to the identification of genetic products expressed in association with tumours and to coding nucleic acids for said products. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are aberrantly expressed in association with tumours, proteins, polypeptides and peptides which are expressed in association with tumours and to the coding nucleic acids for said proteins, polypeptides and peptides.
Type:
Application
Filed:
September 10, 2004
Publication date:
August 12, 2010
Inventors:
Oezlem Tuereci, Ugur Sahin, Michael Koslowski
Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
Type:
Application
Filed:
March 21, 2012
Publication date:
August 2, 2012
Applicants:
JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AG
Inventors:
Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Type:
Grant
Filed:
April 13, 2016
Date of Patent:
January 3, 2023
Assignees:
Astellas Pharma, Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
Inventors:
Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs
Abstract: The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.
Type:
Grant
Filed:
January 9, 2018
Date of Patent:
November 24, 2020
Assignees:
Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universitat Mainz
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Maria Kreuzberg, Sylvia Luxen
Abstract: The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLD-N6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.
Type:
Application
Filed:
July 4, 2011
Publication date:
July 18, 2013
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Maria Kreuzberg, Sylvia Luxen
Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
Type:
Grant
Filed:
July 30, 2014
Date of Patent:
March 31, 2020
Assignees:
BioN Tech AG, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH, Astellas Pharma Inc.
Inventors:
Ugur Sahin, Ozlem Tureci, Korden Walter, Meike Wagner, Maria Kreuzberg, Sabine Hacker, Stefan Jacobs
Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.
Type:
Application
Filed:
September 25, 2013
Publication date:
May 1, 2014
Applicant:
BioNTech AG
Inventors:
Özlem TÜRECI, Ugur SAHIN, Sandra SCHNEIDER, Gerd HELFTENBEIN, Volker SCHLÜTER, Dirk USENER, Philippe THIEL, Michael KOSLOWSKI